A highly effective and practical desensitization regimen: Results in comparable clinical outcomes for multiple myeloma patients with skin rash after immunomodulatory drugs.

被引：0
|
作者：
Firoozmand, Amin
Ali, Naveed
Ahmed, Nausheen
Fu, Pingfu
Cao, Shufen
Brown, George
Schmikla, Hannah
Driscoll, James Joseph
O'Brien, Timothy
Caimi, Paolo Fabrizio
De Lima, Marcos J. G.
Malek, Ehsan
机构：
[1] Univ Hosp Seidman Comprehens Canc Ctr, Cleveland, OH USA
[2] Case Western Reserve Univ, Seidman Canc Ctr, Cleveland, OH 44106 USA
[3] Case Western Reserve Univ, Dept Populat & Quantitat Hlth Sci, Cleveland, OH 44106 USA
[4] Case Western Reserve Univ, Dept Biostats & Epidemiol, Cleveland, OH 44106 USA
[5] Univ Hosp Seidman Canc Ctr, Adult Hematol Malignancies & Stem Cell Transplant, Cleveland, OH USA
[6] Univ Hosp Seidman Canc Ctr, Cleveland, OH USA
[7] Case Comprehens Canc Ctr, Cleveland, OH USA
[8] Univ Hosp Cleveland Med Ctr, Seidman Canc Ctr, Adult Hematol Malignancies & Stem Cell Transplant, Cleveland, OH USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
12104
引用
收藏
页数：2
相关论文
共 11 条
  • [1] Low Dose Daily Corticosteroid Tapering Regimen Allows Highly Effective and Practical Desensitization for Multiple Myeloma Patients with Skin Rash after Immunomodulatory Drugs
    Firoozmand, Amin
    Ali, Naveed
    Ahmed, Nausheen
    Fu, Pingfu
    Cao, Shufen
    Brown, George
    Schmikla, Hannah
    Driscoll, James J.
    O'Brien, Timothy
    Caimi, Paolo
    de Lima, Marcos
    Malek, Ehsan
    BLOOD, 2020, 136
  • [2] Skin rash after immunomodulatory drugs for plasma cell neoplasms: effective practical corticosteroid desensitisation regimen
    Ali, Naveed
    Schmikla, Hannah
    Chopra, Rishil
    Brown, George
    Fu, Pingfu
    Cao, Shufen
    Driscoll, James
    Ravi, Gayathri
    Van Heeckeren, Willem
    Malek, Ehsan
    BMJ SUPPORTIVE & PALLIATIVE CARE, 2024, 14 (E2) : e2199 - e2201
  • [3] A Highly Effective and Practical Corticosteroid Regimen to Overcome Skin Rash Associated with Immunomodulatory Drugs Allowing Reinstitution of Therapy
    Ali, Naveed
    Schmikla, Hannah
    Brown, George
    Cooper, Brenda
    Metheny, Leland
    Caimi, Paolo
    Patel, Seema
    Driscoll, James J.
    de Lima, Marcos
    Malek, Ehsan
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S390 - S391
  • [4] Busulfan and cyclophosphamide as a conditioning regimen for autologous transplantation in patients with multiple myeloma after treatment with proteasome inhibitors and/or immunomodulatory drugs
    Kang, Ka-Won
    Jeon, Min Ji
    Yu, Eun Sang
    Kim, Dae Sik
    Choi, Chul Won
    Lee, Byung-Hyun
    Lee, Se Ryeon
    Sung, Hwa Jung
    Park, Yong
    Kim, Byung Soo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S41 - S41
  • [5] Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors
    Yalniz, Fevzi Firat
    Akkoc, Nihan
    Salihoglu, Ayse
    Ar, M. Cem
    Ongoren, Seniz
    Eskazan, A. Emre
    Soysal, Teoman
    Aydin, Yildiz
    TURKISH JOURNAL OF HEMATOLOGY, 2017, 34 (03) : 233 - 238
  • [6] Understanding the Dose Regimen for Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma (MM) after Prior Proteasome Inhibitors (PIs) and Immunomodulatory Drugs (IMiDs): A Quantitative Pharmacologic Perspective
    Xu, Xu Steven
    Yan, Xiaoyu
    Puchalski, Thomas
    Lonial, Sagar
    Lokhorst, Henk M.
    Voorhees, Peter M.
    Liu, Kevin
    Khan, Imran
    Jansson, Richard
    Ahmadi, Tahamtan
    Ruixo, Juan Jose Perez
    Zhou, Honghui
    Clemens, Pamela L.
    BLOOD, 2015, 126 (23)
  • [7] Combination of Bendamustine, Lenalidomide, and Dexamethasone In Patients with Refractory or Relapsed Multiple Myeloma Is Safe and Highly Effective: Results of a Phase I Clinical Trial
    Lentzsch, Suzanne
    O'Sullivan, Amy
    Kennedy, Ryan
    Gill, Navkiranjit
    Andreas, Carrie
    Gardner, Diane
    Lalo, Silvana
    Burt, Steve
    Redner, Robert L.
    Volkin, Robert
    Roodman, David
    Mapara, Markus Y.
    Viverette, Frank
    Agha, Mounzer
    Zonder, Jeffrey A.
    BLOOD, 2010, 116 (21) : 435 - 435
  • [8] Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial
    Chanan-Khan, Asher
    Miller, Kena C.
    Musial, Laurie
    Padmanabhan, Swaminathan
    Yu, Jihnhee
    Ailawadhi, Sikander
    Sher, Taimur
    Mohr, Alice
    Bernstein, Zale P.
    Barcos, Maurice
    Patel, Mehul
    Iancu, Dan
    Lee, Kelvin
    Czuczman, Myron S.
    LEUKEMIA & LYMPHOMA, 2009, 50 (07) : 1096 - 1101
  • [9] Consolidation with Bortezomib, Thalidomide and Dexamethasone After High Dose Therapy Is Feasible, Safe and Effective In De Novo Multiple Myeloma Patients Who Already Received New Drugs Containing-Induction Regimen.
    Roussel, Murielle
    Doerr, Gaelle
    Vaillant, Willy
    Huynh, Anne
    Attal, Michel
    BLOOD, 2010, 116 (21) : 1253 - 1253
  • [10] Bortezomib-Based Induction Regimen Followed By Autologous Stem Cell Transplantation (ASCT) after Conditioning with MEL200 Is Highly Effective and Well Tolerated in Elderly Multiple Myeloma (MM) Patients up to the Age of 75 Years
    Belotti, Angelo
    Ribolla, Rossella
    Crippa, Claudia
    Cattaneo, Chiara
    Morello, Enrico
    Orlando, Vincenza
    Bianchetti, Nicola
    Ferrari, Samantha
    Bottelli, Chiara
    Schieppati, Francesca
    Roccaro, Aldo M.
    Chiarini, Marco
    Morone, Mario
    Rossi, Giuseppe
    BLOOD, 2017, 130
12